|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| A61P 11/00 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) |
| (11) | Number of the document | 3038643 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14755668.2 |
| Date of filing the European patent application | 2014-08-26 | |
| (97) | Date of publication of the European application | 2016-07-06 |
| (45) | Date of publication and mention of the grant of the patent | 2019-05-01 |
| (46) | Date of publication of the claims translation | 2019-07-25 |
| (86) | Number | PCT/EP2014/068050 |
| Date | 2014-08-26 |
| (87) | Number | WO 2015/028455 |
| Date | 2015-03-05 |
| (30) | Number | Date | Country code |
| 201315487 | 2013-08-30 | GB |
| (72) |
CRAGGS, Graham, GB
HERVÉ, Karine Jeannine Madeleine, GB
MARSHALL, Diane, GB
|
| (73) |
UCB Biopharma SRL,
Allée de la Recherche 60, 1070 Brussels,
BE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antikūnai prieš CSF-1R |
| ANTIBODIES AGAINST CSF-1R |
| Payment date | Validity (years) | Amount | |
| 2025-07-23 | 12 | 289.00 EUR |
| 2026-08-26 |